How to Get Belsomra (Suvorexant) in North Dakota

What Is Suvorexant and Why Is It Prescribed?

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks wake-promoting orexin-A and orexin-B neuropeptides in the lateral hypothalamus. Unlike benzodiazepines or Z-drugs, it does not potentiate GABA signaling. The result is a mechanistically distinct path to sleep onset and maintenance.

Mechanism and Clinical Evidence

The FDA approved Belsomra in August 2014 for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Approval rested on a phase III program that enrolled over 3,000 adults.

In the key trial published by Herring et al. In The Lancet Neurology (2014), suvorexant 40 mg and 20 mg both significantly reduced subjective time to sleep onset (sTSO) and increased subjective total sleep time (sTST) versus placebo at month 1 and month 3 (P<0.001 for all comparisons). The 20 mg dose reduced sTSO by approximately 8 minutes more than placebo in non-elderly adults. Next-morning residual effects were mild and dose-dependent, occurring more frequently at the 40 mg dose that was ultimately not approved.

Who Qualifies

A provider will typically consider suvorexant for adults 18 and older who have chronic insomnia disorder lasting at least three months and who have not responded adequately to sleep hygiene interventions or cognitive behavioral therapy for insomnia (CBT-I). The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia, giving it a "WEAK FOR" recommendation based on moderate-quality evidence.

Telehealth Prescribing in North Dakota

North Dakota law permits telehealth prescribing of Schedule IV controlled substances when the encounter meets the same standard-of-care requirements as an in-person visit. That means a licensed prescriber can evaluate you by synchronous video, document the clinical assessment, and transmit an electronic prescription to a North Dakota pharmacy.

State-Specific Telehealth Rules

The North Dakota Board of Medicine requires that the prescribing clinician hold an active North Dakota license or a valid interstate compact license. Under the Interstate Medical Licensure Compact (IMLC), physicians licensed in member states can obtain expedited North Dakota licensure, broadening the pool of available telehealth prescribers.

How a Typical Telehealth Visit Works

The visit usually takes 15 to 25 minutes. Expect these steps:

1. Intake questionnaire. You complete a sleep history, medication list, and screening tools such as the Insomnia Severity Index (ISI) and the STOP-BANG questionnaire for obstructive sleep apnea.
2. Video consultation. The provider reviews your history, rules out contraindications (narcolepsy, severe hepatic impairment, concomitant strong CYP3A4 inhibitors), and discusses treatment options.
3. Prescription. If suvorexant is appropriate, an e-prescription goes directly to your chosen North Dakota pharmacy.
4. Follow-up. Most platforms schedule a 30-day check-in to assess efficacy and side effects.

No in-person physical exam is mandated by North Dakota statute for a Schedule IV prescription when a synchronous audiovisual encounter has been completed and documented [1].

Who Can Prescribe Belsomra in North Dakota

Three provider types hold independent prescriptive authority for Schedule IV substances in North Dakota: physicians (MD/DO), nurse practitioners (NP), and physician assistants (PA).

MDs and DOs

Any physician with an active North Dakota medical license and a valid DEA registration can prescribe suvorexant without supervision requirements.

Nurse Practitioners

North Dakota grants full practice authority to nurse practitioners. NPs with a DEA registration can prescribe Belsomra independently. No collaborative agreement with a physician is required after the NP meets the state's minimum practice-hour threshold.

Physician Assistants

PAs in North Dakota prescribe under a collaborative agreement with a supervising physician. The agreement must explicitly authorize Schedule IV prescribing. If it does, the PA can prescribe suvorexant directly.

Labs and Pre-Prescription Workup

Suvorexant does not require routine lab monitoring before or during treatment. The pre-prescription workup focuses on ruling out alternative diagnoses and contraindications rather than on blood tests.

Clinical Assessments Before Starting

A thorough evaluation typically includes:

• Sleep diary review (ideally two weeks of data capturing bedtime, wake time, and perceived sleep quality).
• ISI score. A score of 15 or higher suggests moderate-to-severe clinical insomnia [2].
• Screening for obstructive sleep apnea. The STOP-BANG questionnaire identifies patients who may need polysomnography before sedative-hypnotic therapy.
• Medication reconciliation. Suvorexant is metabolized by CYP3A4. Concomitant use of strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) is contraindicated per the FDA label.
• Hepatic function history. Severe hepatic impairment is a contraindication. If liver disease is suspected, a hepatic panel (AST, ALT, bilirubin) may be drawn, but this is situational, not routine.

Do I Need a Sleep Study First?

Not always. The AASM notes that polysomnography is not required for diagnosing chronic insomnia disorder when the clinical history is clear [3]. A sleep study becomes necessary when the provider suspects comorbid sleep apnea, periodic limb movement disorder, or narcolepsy.

Pharmacy Access and 503A Compounding

Once you have a valid prescription, filling it in North Dakota is straightforward. Belsomra is stocked by major retail chains (CVS, Walgreens) and independent pharmacies across the state.

Retail Pharmacy Availability

Most North Dakota pharmacies carry Belsomra or can order it within one to two business days. Rural communities served by a single pharmacy may experience slightly longer lead times. Mail-order pharmacy is another option: the prescription ships directly to your address, typically arriving within five to seven business days.

503A Compounding Pharmacies

North Dakota licenses 503A compounding pharmacies that can prepare suvorexant formulations with a valid patient-specific prescription. This route is relevant when a patient needs an alternative dosage form (for example, a liquid suspension for patients who cannot swallow tablets) or when cost savings on the active ingredient are possible through compounded preparations.

Under FDA guidance on 503A compounding, a pharmacy must compound the drug pursuant to an individual patient prescription and comply with United States Pharmacopeia (USP) standards. North Dakota Board of Pharmacy regulations require that 503A pharmacies shipping within the state hold a current North Dakota pharmacy license.

Estimated Timeline: Prescription to First Dose

| Step | Typical timeframe | |---|---| | Telehealth visit scheduling | Same day to 3 days | | Video consultation | 15 to 25 minutes | | E-prescription transmitted | Immediately after visit | | Retail pharmacy fill | Same day to 2 business days | | Mail-order pharmacy delivery | 5 to 7 business days | | 503A compounding fill | 3 to 10 business days |

Most patients in Fargo, Bismarck, or Grand Forks can fill at a retail pharmacy the same day the prescription is sent.

Insurance Coverage and Prior Authorization

Commercial insurers in North Dakota generally cover Belsomra on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position. Coverage almost always requires prior authorization.

North Dakota Medicaid

North Dakota Medicaid does not cover Belsomra. Patients on Medicaid who need a DORA-class sleep medication should discuss alternatives (such as lemborexant, marketed as Dayvigo) with their provider, or explore the Merck patient assistance program.

What Prior Authorization Requires

Documentation for prior authorization typically includes:

1. Diagnosis. ICD-10 code G47.00 (insomnia, unspecified) or G47.01 (insomnia due to medical condition).
2. Failure of first-line therapy. Evidence that sleep hygiene counseling and at least one generic sedative-hypnotic (e.g., zolpidem, trazodone) were tried and failed or are contraindicated.
3. Clinical notes. The prescriber's assessment supporting the medical necessity of suvorexant specifically.
4. ISI or equivalent score. Documenting symptom severity strengthens the request.

Prior authorization decisions typically take three to seven business days. If denied, most insurers offer a peer-to-peer review within 48 hours [4].

Cost Without Insurance

The average retail price for a 30-day supply of Belsomra 10 mg or 20 mg ranges from $380 to $450 in North Dakota pharmacies. The Merck Belsomra Savings Card may reduce out-of-pocket cost to as low as $30/month for commercially insured patients. Uninsured patients can apply to Merck's patient assistance program for potential zero-cost access.

Transferring a Belsomra Prescription to North Dakota

If you have an existing suvorexant prescription from another state, you can transfer it to a North Dakota pharmacy under specific conditions.

Transfer Rules for Schedule IV Drugs

The DEA allows one-time transfer of Schedule III-V prescriptions between pharmacies that share a real-time online database. In practice, this means pharmacies within the same chain (CVS to CVS, Walgreens to Walgreens) can transfer remaining refills electronically. Independent-to-independent transfers require a pharmacist-to-pharmacist phone call and are limited to one transfer per prescription.

When a New Prescription Is Needed

If no refills remain on the out-of-state prescription, you will need a new prescription from a North Dakota-licensed provider. A telehealth visit with records from your previous prescriber can usually accomplish this in a single session.

Dosing and Practical Guidance

The FDA-approved starting dose is 10 mg taken once per night, within 30 minutes of bedtime, with at least 7 hours of planned sleep remaining. The dose can be increased to 20 mg if 10 mg is tolerated but insufficiently effective.

Why the 5 mg Dose Exists

The 5 mg tablet is reserved for patients taking moderate CYP3A4 inhibitors (diltiazem, verapamil, fluconazole) or those who experience excessive next-day somnolence at 10 mg. The Herring et al. Trial data showed that efficacy at 10 mg was statistically significant for both sleep onset and maintenance endpoints, while the 5 mg dose was not formally studied as a primary dose in registration trials [5].

Food and Timing

Taking suvorexant with or immediately after a high-fat meal delays onset by approximately 1.5 hours. For fastest onset, take the tablet on an empty stomach or at least 2 hours after dinner.

Side Effects and Safety Considerations

The most commonly reported adverse events in clinical trials were somnolence (7% vs. 3% placebo), headache, and dizziness. Suvorexant carries a labeled warning for next-morning impairment, complex sleep behaviors (sleepwalking, sleep-driving), and worsening of depression or suicidal ideation.

Driving Impairment Data

The FDA-mandated driving simulation study found that suvorexant 20 mg did not significantly impair next-morning driving performance when patients slept a full 8 hours. At 40 mg (not approved), impairment was detected. Patients should not drive or operate heavy machinery until they know how the approved dose affects them individually.

Abuse and Dependence Potential

As a Schedule IV substance, suvorexant has a lower abuse liability profile than Schedule II stimulants or Schedule III opioids. In a human abuse potential study, suvorexant at supratherapeutic doses (40 mg, 80 mg, 150 mg) produced "drug liking" scores that were statistically higher than placebo but numerically lower than zolpidem 30 mg. Physical dependence is minimal: the FDA label states that rebound insomnia on the first night after discontinuation was observed in some patients but resolved by night two.

North Dakota-Specific Resources

North Dakota's small population (approximately 780,000 residents) and large geographic area create access challenges in rural counties. These resources can help.

Telepharmacy in Rural ND

North Dakota was the first state to authorize telepharmacy, and more than 80 telepharmacy sites operate across the state. A telepharmacy site can receive and dispense a Belsomra prescription under the remote supervision of a pharmacist located at a central hub pharmacy. This model means even residents in rural western North Dakota can access their medication without a multi-hour drive.

University of North Dakota Center for Sleep

The UND Center for Family Medicine in Minot and Grand Forks can provide sleep evaluations and prescribe suvorexant. Academic centers are a good option when a patient has complex comorbidities requiring polysomnography before initiating any sedative-hypnotic.

State Prescription Drug Monitoring Program

North Dakota's Prescription Drug Monitoring Program (PDMP) tracks all Schedule II through V dispensing. Providers must query the PDMP before prescribing suvorexant. This check adds no delay to the patient experience; it is completed during the visit.